Clinical Trials Browser

Phase 2 × Ovarian Neoplasms × irinotecan sucrosofate × Clear all

NCT04753216 2023-01-19

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Completed

3 enrolled 15 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms